BACKGROUND: Thrombotic microangiopathy (TMA) significantly affects kidney graft survival, but its pathophysiology remains poorly understood. METHODS: In this multicenter, retrospective, case-control paired study designed to control for donor-associated risks, we assessed the recipients' risk factors for de novo TMA development and its effects on graft survival. The study group consists of patients with TMA found in case biopsies from 2000 to 2019 (n = 93), and the control group consists of recipients of paired kidney grafts (n = 93). Graft follow-up was initiated at the time of TMA diagnosis and at the same time in the corresponding paired kidney graft. RESULTS: The TMA group displayed higher peak panel-reactive antibodies, more frequent retransplantation status, and longer cold ischemia time in univariable analysis. In the multivariable regression model, longer cold ischemia times (odds ratio, 1.18; 95% confidence interval [CI], 1.01-1.39; P = 0.043) and higher peak pretransplant panel-reactive antibodies (odds ratio, 1.03; 95% CI, 1.01-1.06; P = 0.005) were found to be associated with increased risk of de novo TMA. The risk of graft failure was higher in the TMA group at 5 y (hazard ratio [HR], 3.99; 95% CI, 2.04-7.84; P < 0.0001). Concomitant rejection significantly affected graft prognosis at 5 y (HR, 6.36; 95% CI, 2.92-13.87; P < 0.001). De novo TMA associated with the active antibody-mediated rejection was associated with higher risk of graft failure at 5 y (HR, 3.43; 95% CI, 1.69-6.98; P < 0.001) compared with other TMA. CONCLUSIONS: Longer cold ischemia and allosensitization play a role in de novo TMA development, whereas TMA as a part of active antibody-mediated rejection was associated with the highest risk for premature graft loss.

3rd Department of Internal Medicine Nephrology Rheumatology and Endocrinology Teaching Hospital Olomouc Czech Republic

Biomedical Centre Faculty of Medicine in Pilsen Charles University Pilsen Czech Republic

Centre for Cardiovascular and Transplantation Surgery Brno Czech Republic

Department of Clinical and Transplant Pathology Institute for Clinical and Experimental Medicine Prague Czech Republic

Department of Internal Medicine 1 Faculty of Medicine in Pilsen Charles University Teaching Hospital Pilsen Czech Republic

Department of Medicine Teaching Hospital Ostrava Czech Republic

Department of Nephrology Institute for Clinical and Experimental Medicine Prague Czech Republic

Department of Paediatrics 2nd Faculty of Medicine Charles University Prague and Motol University Hospital Prague Czech Republic

Hemodialysis Centre Teaching Hospital Hradec Kralove Czech Republic

Transplant Center Institute for Clinical and Experimental Medicine Prague Czech Republic

Transplant Laboratory Institute for Clinical and Experimental Medicine Prague Czech Republic

Zobrazit více v PubMed

Garg N, Rennke HG, Pavlakis M, et al. . De novo thrombotic microangiopathy after kidney transplantation. Transplant Rev (Orlando). 2018;32:58–68. PubMed

Caires RA, Marques ID, Repizo LP, et al. . De novo thrombotic microangiopathy after kidney transplantation: clinical features, treatment, and long-term patient and graft survival. Transplant Proc. 2012;44:2388–2390. PubMed

Reynolds JC, Agodoa LY, Yuan CM, et al. . Thrombotic microangiopathy after renal transplantation in the United States. Am J Kidney Dis. 2003;42:1058–1068. PubMed

Zarifian A, Meleg-Smith S, O’donovan R, et al. . Cyclosporine-associated thrombotic microangiopathy in renal allografts. Kidney Int. 1999;55:2457–2466. PubMed

Satoskar AA, Pelletier R, Adams P, et al. . De novo thrombotic microangiopathy in renal allograft biopsies-role of antibody-mediated rejection. Am J Transplant. 2010;10:1804–1811. PubMed

Teixeira CM, Tedesco Silva Junior H, Moura LAR, et al. . Clinical and pathological features of thrombotic microangiopathy influencing long-term kidney transplant outcomes. PLoS One. 2020;15:e0227445. PubMed PMC

Ponticelli C, Banfi G. Thrombotic microangiopathy after kidney transplantation. Transpl Int. 2006;19:789–794. PubMed

Loupy A, Haas M, Roufosse C, et al. . The Banff 2019 Kidney Meeting Report (I): updates on and clarification of criteria for T cell- and antibody-mediated rejection. Am J Transplant. 2020;20:2318–2331. PubMed PMC

Cernoch M, Viklicky O. Complement in kidney transplantation. Front Med (Lausanne). 2017;4:66. PubMed PMC

Jodele S, Zhang K, Zou F, et al. . The genetic fingerprint of susceptibility for transplant-associated thrombotic microangiopathy. Blood. 2016;127:989–996. PubMed PMC

Gomez SA, Abrey-Recalde MJ, Panek CA, et al. . The oxidative stress induced in vivo by Shiga toxin-2 contributes to the pathogenicity of haemolytic uraemic syndrome. Clin Exp Immunol. 2013;173:463–472. PubMed PMC

Louise CB, Obrig TG. Human renal microvascular endothelial cells as a potential target in the development of the hemolytic uremic syndrome as related to fibrinolysis factor expression, in vitro. Microvasc Res. 1994;47:377–387. PubMed

Meri S, Pangburn MK. Discrimination between activators and nonactivators of the alternative pathway of complement: regulation via a sialic acid/polyanion binding site on factor H. Proc Natl Acad Sci U S A. 1990;87:3982–3986. PubMed PMC

Reyes-Vargas E, Pavlov IY, Martins TB, et al. . Binding of anti-HLA class I antibody to endothelial cells produce an inflammatory cytokine secretory pattern. J Clin Lab Anal. 2009;23:157–160. PubMed PMC

Azuma H, Nadeau K, Takada M, et al. . Cellular and molecular predictors of chronic renal dysfunction after initial ischemia/reperfusion injury of a single kidney. Transplantation. 1997;64:190–197. PubMed

Ponticelli C. Ischaemia-reperfusion injury: a major protagonist in kidney transplantation. Nephrol Dial Transplant. 2014;29:1134–1140. PubMed

Agustian PA, Bockmeyer CL, Modde F, et al. . Glomerular mRNA expression of prothrombotic and antithrombotic factors in renal transplants with thrombotic microangiopathy. Transplantation. 2013;95:1242–1248. PubMed

Sis B, Jhangri GS, Bunnag S, et al. . Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. Am J Transplant. 2009;9:2312–2323. PubMed

Hidalgo LG, Sis B, Sellares J, et al. . NK cell transcripts and NK cells in kidney biopsies from patients with donor-specific antibodies: evidence for NK cell involvement in antibody-mediated rejection. Am J Transplant. 2010;10:1812–1822. PubMed

Drachenberg CB, Papadimitriou JC. Endothelial injury in renal antibody-mediated allograft rejection: a schematic view based on pathogenesis. Transplantation. 2013;95:1073–1083. PubMed

Salazar ID, Merino López M, Chang J, et al. . Reassessing the significance of intimal arteritis in kidney transplant biopsy specimens. J Am Soc Nephrol. 2015;26:3190–3198. PubMed PMC

Wohlfahrtova M, Hruba P, Klema J, et al. . Early isolated V-lesion may not truly represent rejection of the kidney allograft. Clin Sci (Lond). 2018;132:2269–2284. PubMed PMC

Wu K, Budde K, Schmidt D, et al. . The inferior impact of antibody-mediated rejection on the clinical outcome of kidney allografts that develop de novo thrombotic microangiopathy. Clin Transplant. 2016;30:105–117. PubMed

Young BA, Marsh CL, Alpers CE, et al. . Cyclosporine-associated thrombotic microangiopathy/hemolytic uremic syndrome following kidney and kidney-pancreas transplantation. Am J Kidney Dis. 1996;28:561–571. PubMed

Schwimmer J, Nadasdy TA, Spitalnik PF, et al. . De novo thrombotic microangiopathy in renal transplant recipients: a comparison of hemolytic uremic syndrome with localized renal thrombotic microangiopathy. Am J Kidney Dis. 2003;41:471–479. PubMed

Louvar DW, Li N, Snyder J, et al. . “Nature versus nurture” study of deceased-donor pairs in kidney transplantation. J Am Soc Nephrol. 2009;20:1351–1358. PubMed PMC

Traynor C, O’Kelly P, Denton M, et al. . Concordance of outcomes of pairs of kidneys transplanted into different recipients. Transpl Int. 2012;25:918–924. PubMed

Westra D, Volokhina EB, van der Molen RG, et al. . Serological and genetic complement alterations in infection-induced and complement-mediated hemolytic uremic syndrome. Pediatr Nephrol. 2017;32:297–309. PubMed PMC

Le Quintrec M, Lionet A, Kamar N, et al. . Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation. Am J Transplant. 2008;8:1694–1701. PubMed

Michielsen LA, Wisse BW, Kamburova EG, et al. . A paired kidney analysis on the impact of pre-transplant anti-HLA antibodies on graft survival. Nephrol Dial Transplant. 2019;34:1056–1063. PubMed

Kayler LK, Magliocca J, Zendejas I, et al. . Impact of cold ischemia time on graft survival among ECD transplant recipients: a paired kidney analysis. Am J Transplant. 2011;11:2647–2656. PubMed

Kaplan B, Schold JD, Meier-Kriesche HU. Long-term graft survival with neoral and tacrolimus: a paired kidney analysis. J Am Soc Nephrol. 2003;14:2980–2984. PubMed

Doshi MD, Garg N, Reese PP, et al. . Recipient risk factors associated with delayed graft function: a paired kidney analysis. Transplantation. 2011;91:666–671. PubMed

Schinstock CA, Mannon RB, Budde K, et al. . Recommended treatment for antibody-mediated rejection after kidney transplantation: the 2019 expert consensus from the Transplantion Society Working Group. Transplantation. 2020;104:911–922. PubMed PMC

MCPggaac haplotype is associated with poor graft survival in kidney transplant recipients with de novo thrombotic microangiopathy